Social Media Ideas for Alks

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000

The insider still has significant holdings in the company, signaling confidence.

Alkane Resources Ltd (ALK:CA) Presents at Mining Forum Americas 2026 - Slideshow

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

Alsea, S.A.B. de C.V. (ALSSF) Q3 2026 Earnings Call Transcript

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Alumis’ TYK2 drug fails in key lupus study

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis. 

Broker’s Call: Alkem Laboratories (Buy)

Elara Securities

Axsome rises on Auvelity prescription data

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Earlier this month, we covered Definium Therapeutics’ second Phase 3 readout, this time pertaining to its first LSD (DT120) for generalised anxiety disorder (GAD) study. (See Smoot...

Alkermes Must Face Bulk Of Addiction Treatment Drug Suit

A Massachusetts federal judge largely refused Thursday to let Alkermes duck a proposed class action alleging it tricked the U.S. Patent and Trademark Office into granting a patent...